Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Long-Term Debt Repayments (2017 - 2025)

Editas Medicine (EDIT) has disclosed Long-Term Debt Repayments for 4 consecutive years, with $2.9 million as the latest value for Q1 2025.

  • Quarterly Long-Term Debt Repayments changed N/A to $2.9 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Sep 2025, up 1116.95% year-over-year, with the annual reading at $857000.0 for FY2018, 42.83% up from the prior year.
  • Long-Term Debt Repayments for Q1 2025 was $2.9 million at Editas Medicine, up from $236000.0 in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $2.9 million in Q1 2025, with the low at $2.9 million in Q1 2025.